NCT00994500 2013-07-02Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaNational Cancer Institute (NCI)Phase 1 Completed20 enrolled